Krystal Biotech Profit Margin

Krystal Biotech (KRYS) currently reports a profit margin of 54.82% as of June 2026. That compares with 40.85% in the prior-year period — up 34.2% year over year. That is above the Healthcare sector average of 14.41%. Use the charts on this page to explore Krystal Biotech's profit margin history and peer comparisons.

Krystal Biotech's profit margin increased from 40.85% to 54.82% — a 34.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Krystal Biotech's profit margin of 54.82% is higher than the Healthcare sector average of 14.41%. That is roughly 280.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Krystal Biotech's current 54.82% should be judged against Healthcare norms (sector average: 14.41%) and against KRYS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 54.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.41%. From there, open related valuation or income-statement pages for Krystal Biotech, and consider following KRYS for alerts when major investors trade the stock.